Outlook is neutral, with stock confined to a band of ±3%
Strategy has +42% ROI potential and 20% overvalued
NVO Novo Nordisk A/S87.51+6.41 (+7.9%)
NVO 87.13+6.03 (+7.4%)Novo Nordisk A/S
NVO Novo Nordisk A/S79.19-3.88 (-4.7%)
NVO Novo Nordisk A/S83.56+0.64 (+0.8%)